DHA-Triacylglycerol Accumulation in Tacrolimus-Induced Nephrotoxicity Identified by Lipidomic Profiling
- PMID: 40806677
- PMCID: PMC12347805
- DOI: 10.3390/ijms26157549
DHA-Triacylglycerol Accumulation in Tacrolimus-Induced Nephrotoxicity Identified by Lipidomic Profiling
Abstract
Tacrolimus (TAC)-induced chronic nephrotoxicity (TAC nephrotoxicity) remains a major contributor to late allograft dysfunction in kidney transplant recipients. Although detailed mechanisms remain incompletely understood, our previous metabolomic studies revealed disruptions in carnitine-related and redox pathways, suggesting impaired mitochondrial β-oxidation of fatty acids. To further characterize metabolic alterations associated with this condition, we conducted an untargeted lipidomic analysis of renal tissues using a murine model of TAC nephrotoxicity. TAC (1 mg/kg/day) or saline was subcutaneously administered to male ICR mice for 28 days, and kidney tissues were harvested for comprehensive lipidomic profiling. Lipidomic analysis was performed with liquid chromatography-tandem mass spectrometry (p < 0.05, n = 5/group). Triacylglycerols (TGs) were the predominant lipid class identified. TAC-treated mice exhibited reduced levels of unsaturated TG species with low carbon numbers, whereas TGs with higher carbon numbers and various degrees of unsaturation were increased. All detected TGs containing docosahexaenoic acid (DHA) showed an increasing trend in TAC-treated kidneys. Although accumulation of polyunsaturated TGs has been previously observed in chronic kidney disease, the preferential increase in DHA-containing TGs appears to be a unique feature of TAC-induced nephrotoxicity. These results suggest that DHA-enriched TGs may serve as a metabolic signature of TAC nephrotoxicity and offer new insights into its pathophysiology.
Keywords: calcineurin inhibitor; docosahexaenoic acid; lipidomics; renal injury; tacrolimus; triacylglycerol profiling.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.Cochrane Database Syst Rev. 2015 Oct 12;2015(10):CD009698. doi: 10.1002/14651858.CD009698.pub2. Cochrane Database Syst Rev. 2015. PMID: 26457607 Free PMC article.
-
Study on the modulation of kidney and liver function of rats with diabetic nephropathy by Huidouba through metabolomics.J Ethnopharmacol. 2025 Jul 24;351:120136. doi: 10.1016/j.jep.2025.120136. Epub 2025 Jun 11. J Ethnopharmacol. 2025. PMID: 40513925
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Baumgart D.C., Pintoffl J.P., Sturm A., Wiedenmann B., Dignass A.U. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am. J. Gastroenterol. 2006;101:1048–1056. doi: 10.1111/j.1572-0241.2006.00524.x. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous